Developing CSCO Lung Cancer Practice Guidelines Stratified by Resource Availability and Treatment Value

le Zhou, Qing, Wu, Yi-Long
Foilsithe in J Glob Oncol (2016)

Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review

le Su, Shan, Wu, Yi-Long
Foilsithe in J Hematol Oncol (2017)

Immunotherapy in the Asiatic population: any differences from Caucasian population?

le Peng, Lunxi, Wu, Yi-Long
Foilsithe in J Thorac Dis (2018)

Surgery in oligometastatic NSCLC patients in the targeted therapy era

le Zhang, Qi, Wu, Yi-Long
Foilsithe in Lung Cancer Manag (2016)

Spatial Pattern and Dynamic Change of Vegetation Greenness From 2001 to 2020 in Tibet, China

le Fugen Jiang, Fugen Jiang, Fugen Jiang, Muli Deng, Muli Deng, Muli Deng, Yi Long, Yi Long, Yi Long, Hua Sun, Hua Sun, Hua Sun
Foilsithe 2022-04-01

Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence

le E-E Ke, Yi-Long Wu
Foilsithe 2016-06-01

An Efficient Synthesis of 5-Amido-3-Hydroxy-4-Pyrones as Inhibitors of Matrix Metalloproteinases

le Yan, Yi-Long, Cohen, Seth M.
Foilsithe 2007

1,3-Dimethyl 5-(4,4,5,5-tetra­methyl-1,3,2-dioxaborolan-2-yl)benzene-1,3-dicarboxyl­ate

le Yi, Long-tao, Liu, Zhi-qiang
Foilsithe 2012

Novel agents and strategies for overcoming EGFR TKIs resistance

le Niu, Fei-Yu, Wu, Yi-Long
Foilsithe 2014

Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib

le Niu, Fei-Yu, Wu, Yi-Long
Foilsithe in Onco Targets Ther (2015)

Insight into early-phase trials for lung cancer in the United States

le Yang, Jin-Ji, Wu, Yi-Long
Foilsithe in Chin J Cancer (2015)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 bloc...

le Wu, Si-Pei, Wu, Yi-Long
Foilsithe in J Immunother Cancer (2015)

CSCO joins ESMO Open—Cancer Horizons

le Zielinski, Christoph C, Wu, Yi-Long
Foilsithe in ESMO Open (2016)

Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China

le Gou, Lan-Ying, Wu, Yi-Long
Foilsithe in Lung Cancer (Auckl) (2014)

Misuse of Pirated Drugs: Why China? What Is Next?

le Sun, Hui-wen, Wu, Yi-Long
Foilsithe in J Glob Oncol (2016)

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

le Liu, Si-Yang, Wu, Yi-Long
Foilsithe in J Hematol Oncol (2017)

Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence

le Ke, E-E, Wu, Yi-Long
Foilsithe in Ther Adv Respir Dis (2016)

Adjuvant TKIs: still an optimal choice

le Liu, Si-Yang, Wu, Yi-Long
Foilsithe in J Thorac Dis (2018)

Personalized adjuvant treatment: go through the past to the future

le Liu, Si-Yang, Wu, Yi-Long
Foilsithe in J Thorac Dis (2019)

Biomarker for personalized immunotherapy

le Liu, Si-Yang, Wu, Yi-Long
Foilsithe in Transl Lung Cancer Res (2019)